Theravance Biopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2013 | — | $-17.0M | $0 |
| FY2014 | — | $289.8M | $277.5M |
| FY2015 | — | $243.1M | $112.7M |
| FY2016 | — | $350.2M | $344.7M |
| FY2017 | $223.7M | $115.2M | $89.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2013 | — | $-17.0M | $0 |
| FY2014 | — | $289.8M | $277.5M |
| FY2015 | — | $243.1M | $112.7M |
| FY2016 | — | $350.2M | $344.7M |
| FY2017 | $223.7M | $115.2M | $89.0M |